Our 2001 acquisition of Knoll Pharmaceuticals positioned Abbott as a leader in biotechnology with Humira, a biologic for treating several debilitating autoimmune diseases. Our clinical development expertise and superior commercial execution have made Humira one of the fastest-growing biologics on the market today.
Anatomy of a growth strategy
Humira represents a pipeline within a product, with the potential to treat multiple autoimmune diseases. It is currently marketed for rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis (AS) and Crohn’s disease. Since its launch in 2003, Humira has grown to more than $2 billion in annual sales — Abbott’s largest brand ever. With three more indications in development, it will remain an important therapy for years to come.
Building a growth driver:
Humira blocks a protein called tumor necrosis factor (TNF), which plays a key role in causing inflammation. Excess TNF is associated with the progression of autoimmune diseases, such as RA.
Additional indications in development: